Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

by Wray, Sibyl , Xu, Yihuan , Steinman, Lawrence , Power, Sean A. , Alvarez, Enrique , Wynn, Daniel , Selmaj, Krzysztof , Weiss, Michael S. , Hsu, Yanzhi , Cutter, Gary , Bosco, Jenna A. , Huang, DeRen , Lee, Lily , Qian, Peiqing , Miskin, Hari P. , Mok, Koby , Fox, Edward , Hartung, Hans-Peter , Robertson, Derrick , Cree, Bruce A.C.

in Allergy / Anti-Inflammatory Agents, Non-Steroidal - therapeutic use / Antibodies / Antibodies, Monoclonal - therapeutic use / Crotonates / Cytolysis / Double-Blind Method / Drug dosages / Gadolinium / Gadolinium - therapeutic use / Humans / Hydroxybutyrates / Immunology / Immunosuppressive Agents - therapeutic use / Inflammatory Disease / Intravenous administration / Laboratories / Lesions / Lymphocytes B / Magnetic Resonance Imaging / Monoclonal antibodies / Multiple Sclerosis / Multiple Sclerosis - complications / Multiple Sclerosis - diagnostic imaging / Multiple Sclerosis - drug therapy / Multiple Sclerosis - pathology / Multiple Sclerosis, Relapsing-Remitting - complications / Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging / Multiple Sclerosis, Relapsing-Remitting - drug therapy / Multiple Sclerosis, Relapsing-Remitting - pathology / Neuroimaging / Neurology / Neurosurgery / Nitriles / Placebos / Standard scores / Statistical analysis / Toluidines

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

2022

Confirm

Do you wish to request the book?

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Wray, Sibyl,

Xu, Yihuan,

Steinman, Lawrence,

Power, Sean A.,

Alvarez, Enrique,

Wynn, Daniel,

Selmaj, Krzysztof,

Weiss, Michael S.,

Hsu, Yanzhi,

Cutter, Gary,

Bosco, Jenna A.,

Huang, DeRen,

Lee, Lily,

Qian, Peiqing,

Miskin, Hari P.,

Mok, Koby,

Fox, Edward,

Hartung, Hans-Peter,

Robertson, Derrick,

Cree, Bruce A.C.

2022

Overview

In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Allergy

/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use

/ Antibodies

/ Antibodies, Monoclonal - therapeutic use

/ Crotonates

/ Cytolysis

/ Double-Blind Method